Документ не применяется. Подробнее см. Справку

Список литературы

1. Bates G., Tabrizi S., Jones L. Huntington's disease/G. Bates, S. Tabrizi, L. Jones, Oxford University Press (UK), 2014.

2. Bates G.P. et al. Huntington disease//Nature Reviews Disease Primers. 2015. (1). С. 15005.

3. Kay C. et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population//Neurology. 2016. N 3 (87). С. 282 - 288.

4. Killoran A., Biglan K.M. Current therapeutic options for Huntington's disease: Good clinical practice versus evidence-based approaches?//Movement disorders. 2014. N 11 (29). С. 1404 - 1413.

5. Kivela J.E. et al. Anesthetic Management of Patients with Huntington Disease//Anesthesia & Analgesia. 2010. N 2 (110). С. 515 - 523.

6. Nance M. et al. A Physician's Guide to the Management of Huntington's Disease//2011.

7. Pringsheim T. et al. The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis//Movement disorders. 2012. N 9 (27). С. 1083 - 1091.

8. Rawlins M.D. et al. The Prevalence of Huntington's Disease//Neuroepidemiology. 2016. N 2 (46). С. 144 - 153.

9. Reilmann R., Leavitt B.R., Ross C.A. Diagnostic criteria for Huntington's disease based on natural history//Movement disorders. 2014. N 11 (29). C. 1335 - 1341.

10. Shoulson I. et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype//Quantification of neurologic deficit. Boston: Butterworths. 1989. С. 271 - 283.

11. Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics//European Journal of Human Genetics. 2009. N 6 (17). С. 720 - 721.

12. 00000002.wmz G., et al. Guidelines for clinical pharmacological practices in Huntington"s disease//Revue Neurologique. 2016. N 8-9 (172). С. 423 - 432.